Haemonetics Corporation (HAE)vsJohnson & Johnson (JNJ)
HAE
Haemonetics Corporation
$52.67
-5.30%
HEALTHCARE · Cap: $2.75B
JNJ
Johnson & Johnson
$224.62
-0.41%
HEALTHCARE · Cap: $546.90B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 7210% more annual revenue ($96.36B vs $1.32B). JNJ leads profitability with a 21.8% profit margin vs 13.3%. HAE appears more attractively valued with a PEG of 0.91. HAE earns a higher WallStSmart Score of 64/100 (C+).
HAE
Buy64
out of 100
Grade: C+
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+44.1%
Fair Value
$102.84
Current Price
$52.67
$50.17 discount
Margin of Safety
-40.3%
Fair Value
$160.72
Current Price
$224.62
$63.90 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 21.0%
Earnings expanding 28.4% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Distress zone — elevated risk
Elevated debt levels
Revenue declined 2.7%
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : HAE
The strongest argument for HAE centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.91 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : HAE
The primary concerns for HAE are Altman Z-Score, Debt/Equity, Revenue Growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
HAE profiles as a declining stock while JNJ is a mature play — different risk/reward profiles.
HAE carries more volatility with a beta of 0.36 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
HAE scores higher overall (64/100 vs 59/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?